Cambridge, MA-based TransMolecular, a developer of cancer drugs based on a molecule derived from scorpion venom, said today it has named Robert Radie as its president and CEO. Before joining TransMolecular as a business development consultant, Radie held leadership roles at Prestwick Pharmaceuticals, Morphotek, and Vicuron Pharmaceuticals.

Rebecca is Xconomy's co-founder. Follow @

• Share on Facebook
• Share on Twitter
• LinkedIn
• Email
• Reprints

Trending on Xconomy

• Biogen’s Ehlers Leaving for Apple Tree, Steps Into Limelight as CEO
• Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs
• ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More